Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer

Wolfgang Janni; Hans-Christian Kolberg; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Christian Jackisch; Frederik Marme; Manuel Hörner; Katharina Keller; Chloë Goossens; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P. Lux; Maggie Banys-Paluchowski; Achim Wöckel; Nadia Harbeck; Elmar Stickeler; Rupert Bartsch; Bahriye Aktas; Andreas Schneeweiss; Johannes Ettl; Florin-Andrei Taran; Diana Lüftner; Rachel Würstlein; Julia C. Radosa

doi:10.1055/a-2533-2783

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2025; 85(05): 493-506
DOI: 10.1055/a-2533-2783

GebFra Science

Review

Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer

Article in several languages: English | deutsch

Authors

Wolfgang Janni

¹Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Hans-Christian Kolberg

²Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Andreas D. Hartkopf

³Department of Gynecology and Obstetrics, Tübingen University Hospital, Tübingen, Germany
Tanja N. Fehm

⁴Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

⁵Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), Düsseldorf, Germany
Manfred Welslau

⁶Onkologie Aschaffenburg, Aschaffenburg, Germany
Volkmar Müller

⁷Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Florian Schütz

⁸Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus, Speyer, Germany
Peter A. Fasching

⁹Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

¹⁰Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
Christian Jackisch

¹¹Evangelische Kliniken Essen Mitte, Essen, Germany
Frederik Marme

¹²Universitätsmedizin Mannheim, Frauenklinik, Mannheim, Germany
Manuel Hörner

⁹Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

¹⁰Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
Katharina Keller

⁹Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

¹⁰Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
Chloë Goossens

⁹Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

¹⁰Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
Erik Belleville

¹³ClinSol GmbH & Co. KG, Würzburg, Germany
Michael Untch

¹⁴Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
Marc Thill

¹⁵Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
Hans Tesch

¹⁶Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
Nina Ditsch

¹⁷Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
Michael P. Lux

¹⁸Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
Maggie Banys-Paluchowski

¹⁹Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Achim Wöckel

²⁰Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Nadia Harbeck

²¹Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
Elmar Stickeler

²²Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
Rupert Bartsch

²³Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
Bahriye Aktas

²⁴Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
Andreas Schneeweiss

²⁵National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
Johannes Ettl

²⁶Cancer Center Kempten/Allgäu, Klinikverbund Allgäu gGmbH, Department of Obstetrics and Gynecology and Department of Oncology and Palliative Care, Klinikverbund Allgäu, Klinik für Frauenheilkunde und Gynäkologie, Kempten, Germany
Florin-Andrei Taran

²⁷Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
Diana Lüftner

²⁸Immanuel Hospital Märkische Schweiz, Buckow, Germany & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany
Rachel Würstlein

²¹Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
Julia C. Radosa

²⁹Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany

Abstract

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

Keywords

breast cancer - biomarker - clinical studies - early breast cancer

Full Text

References

References/Literatur
1 Stoppa-Lyonnet D, Ansquer Y, Dreyfus H. et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18: 4053-4059
2 Robson ME, Chappuis PO, Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17
3 Copson ER, Maishman TC, Tapper WJ. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018; 19: 169-180
4 Fasching PA, Loibl S, Hu C. et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36: 2281-2287
5 Fasching PA, Hu C, Hart SN. et al. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer 2024; 10: 57
6 Goodwin PJ, Phillips KA, West DW. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 2012; 30: 19-26
7 Huzarski T, Byrski T, Gronwald J. et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 2013; 31: 3191-3196
8 Verhoog LC, Brekelmans CT, Seynaeve C. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-321
9 Rennert G, Bisland-Naggan S, Barnett-Griness O. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 115-123
10 Hahnen E, Lederer B, Hauke J. et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3: 1378-1385
11 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer-Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39: 1619-1630
12 Cybulski C, Kluzniak W, Huzarski T. et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 2015; 16: 638-644
13 Schroth W, Goetz MP, Hamann U. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436
14 Fasching PA, Loehberg CR, Strissel PL. et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008; 112: 89-98
15 Hein A, Lambrechts D, von Minckwitz G. et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137: 2981-2988
16 Hein A, Rack B, Li L. et al. Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. Geburtshilfe Frauenheilkd 2017; 77: 651-659
17 Pirie A, Guo Q, Kraft P. et al. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Res 2015; 17: 58
18 Weischer M, Nordestgaard BG, Pharoah P. et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012; 30: 4308-4316
19 Muranen TA, Blomqvist C, Dork T. et al. Patient survival and tumor characteristics associated with CHEK2:p. I157 T – findings from the Breast Cancer Association Consortium. Breast Cancer Res 2016; 18: 98
20 Guo Q, Schmidt MK, Kraft P. et al. Identification of novel genetic markers of breast cancer survival. J Natl Cancer Inst 2015; 107: djv081
21 Stevens KN, Fredericksen Z, Vachon CM. et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012; 72: 1795-1803
22 Stevens KN, Vachon CM, Lee AM. et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 2011; 71: 6240-6249
23 Breast Cancer Association Consortium. Mavaddat N, Dorling L, Carvalho S. et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol 2022; 8: e216744
24 Ghoussaini M, Fletcher O, Michailidou K. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-318
25 Kuchenbaecker KB, Ramus SJ, Tyrer J. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015; 47: 164-171
26 Michailidou K, Beesley J, Lindstrom S. et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373-380
27 Michailidou K, Hall P, Gonzalez-Neira A. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353-361 361e1–361e2
28 Milne RL, Kuchenbaecker KB, Michailidou K. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 2017; 49: 1767-1778
29 Michailidou K, Lindstrom S, Dennis J. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 2017; 551: 92-94
30 Mavaddat N, Michailidou K, Dennis J. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 2019; 104: 21-34
31 Mavaddat N, Michailidou K, Dennis J. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 2019; 104: 21-34
32 Yiangou K, Mavaddat N, Dennis J. et al. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. medRxiv 2024;
33 Lopes Cardozo JMN, Andrulis IL, Bojesen SE. et al. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. J Clin Oncol 2023; 41: 1849-1863
34 Nelson HD, Fu R, Zakher B. et al. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2019. Evidence Synthesis No. 180. AHRQ Publication No. 19-05249-EF‑1
35 Buijs SM, Koolen SLW, Mathijssen RHJ. et al. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?. Drugs 2024; 84: 385-401
36 Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A. et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin Oncol 2023; 41: 3116-3121
37 Schroth W, Hamann U, Fasching PA. et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010; 16: 4468-4477
38 Murdter TE, Schroth W, Bacchus-Gerybadze L. et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717
39 Province MA, Goetz MP, Brauch H. et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2014; 95: 216-227
40 Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer 2020; 20: 417-436
41 Ditsch N, Wöcke A, Untch M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17: 403-420
42 Cuzick J, Chu K, Keevil B. et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. Lancet Oncol 2024; 25: 108-116
43 Pusztai L, Denkert C, OʼShaughnessy J. et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 2024; 35: 429-436
44 Dent R, Cortés J, Pusztai L. et al. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst 2024; 116: 1654-1663
45 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567
46 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821
47 Schmid P, Cortes J, Dent R. et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 2024; 391: 1981-1991
48 Loibl S, Schneeweiss A, Huober J. et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33: 1149-1158
49 Ignatiadis M, Bailey A, McArthur H. et al. Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. Cancer Res 2024; 84 (9_Supplement): GS01-3
50 Conte PF, Dieci MV, Bisagni G. et al. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. J Clin Oncol 2024; 42 (17_suppl): LBA500
51 Kalinsky K, Barlow WE, Gralow JR. et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 2021; 385: 2336-2347
52 Piccart M, van ʼt Veer LJ, Poncet C. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021; 22: 476-488
53 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121
54 Nitz UA, Gluz O, Kummel S. et al. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol 2022; 40: 2557-2567
55 Kalinsky KM, Barlow WE, Gralow JR. et al. Distant-disease free interval in participants (pts) with 1–3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) ± chemotherapy (CT): SWOG s1007 (RxPONDER). San Antonio Breast Cancer Symposium 2021; 2021: GS2-07
56 Moolhuijsen LME, Visser JA. Anti-Mullerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab 2020; 105: 13
57 Anderson RA, Mansi J, Coleman RE. et al. The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2017; 87: 58-64
58 Trapp E, Steidl J, Rack B. et al. Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A study. Breast 2017; 35: 130-135
59 Ruddy KJ, Schaid DJ, Partridge AH. et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril 2019; 112: 731-739.e1
60 Kalinsky K, Barlow WE, Pathak HB. et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). J Clin Oncol 2024; 42 (16_suppl): 505
61 Johnston SRD, Toi M, OʼShaughnessy J. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24: 77-90
62 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581
63 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987-3998
64 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024; 390: 1080-1091
65 Fasching PA, Hack CC, Nabieva N. et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. Eur J Cancer 2024; 209: 114239
66 Schäffler H, Mergel F, Pfister K. et al. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers. Int J Mol Sci 2023; 24: 16366
67 Hack CC, Maass N, Aktas B. et al. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study. Geburtshilfe Frauenheilkd 2024; 84: 185-195
68 Yardley DA, Untch M, Barrios sr. CH. et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. J Clin Oncol 2024; 42 (16_suppl): 512
69 Tolaney SM, Garrett-Mayer E, White J. et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol 2021; 39: 2720-2731
70 Loi S, Johnston SRD, Arteaga CL. et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol 2024; 42 (17_suppl):: LBA507
71 clinicaltrials.gov. Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer (SURVIVE). 2023. Accessed April 15, 2023 at: https://clinicaltrialsgov/ct2/show/NCT05658172
72 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
73 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
74 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
75 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
76 Rugo HS, Bardia A, Marmé F. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1423-1433
77 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
78 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
79 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
80 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
81 Cuzick J, Sestak I, Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16: 67-75
82 Goss PE, Ingle JN, Ales-Martinez JE. et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-2391
83 Fisher B, Costantino JP, Wickerham DL. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662
84 Powles TJ, Ashley S, Tidy A. et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283-290
85 Veronesi U, Maisonneuve P, Rotmensz N. et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727-737